CBMG Breaks Ground on Phase II CAR-T Commercial Manufacturing Facility Amid IPO Filing
AbelZeta
Developer of Immune Cell and Stem Cell Therapy Products
Johnson & Johnson
Medical Device R&D and Manufacturer
AstraZeneca
Pharmaceutical Technology Research and Development Provider
Recently, Cellular Biomedicine Group (hereinafter referred to as "CBMG" or "the Company") held a grand groundbreaking ceremony for Phase II of its CAR-T commercial production base. This move marks a solid step forward in CBMG's efforts to advance the localized production and market-oriented operation of CAR-T cell therapies in China.
The groundbreaking of the CAR-T commercial production base this time is an important milestone in Cellular Biomedicine Group's overall commercialization strategy. After this expansion,The total area of the company's GMP production facilities will exceed 20,000 square meters.The new commercialization base will be designed and constructed according to international advanced standards, serving as a core production platform for the company’s international cooperation with Johnson & Johnson and AstraZeneca. It will be used to carry the commercial production of future products and play a key role in meeting the rapidly growing market demand for CAR-T therapies.
Cellular Biomedicine Group (Shanghai) Ltd's Core Management Team and Employees Cut the Ribbon Together
Cellular Biomedicine Group (Shanghai) Ltd has been continuously increasing its R&D efforts and deepening its global commercialization strategic layout in recent years. At the end of last year, during the ASH Annual Meeting, the company presented long-term follow-up data on its novel anti-CD19/CD20 dual-target CAR-T (C-CAR039) for the treatment of relapsed or refractory large B-cell non-Hodgkin lymphoma patients. The results demonstrated profound and sustained clinical efficacy. According to the study, among evaluable r/r NHL patients, with a median follow-up time of 30.0 months, the overall response rate was 91.5%, and the complete response rate was 85.1%, drawing widespread attention within the industry. As R&D has continued to deepen and product data has shown excellent performance, Cellular Biomedicine Group has attracted interest from several international pharmaceutical giants. The company first reached a global collaboration and licensing agreement with Janssen Pharmaceuticals under Johnson & Johnson, followed by a co-development agreement with AstraZeneca for a novel GPC3-armored CAR-T therapy in China. These milestones indicate that Cellular Biomedicine Group’s cell therapy has reached an internationally leading level in terms of R&D strength, production standards, and innovation.
Cellular Biomedicine Group (Shanghai) Ltd Chairman and CEO Billy Liu's Speech
Cellular Biomedicine Group (Shanghai) Ltd Chairman and CEO Liu Bizuo stated：
"The construction of this commercial production base is another milestone for the company in advancing its international strategic layout. The CAR-T cell therapy with the company's proprietary intellectual property has rapidly transitioned from laboratory research to the commercial preparation stage. Collaborating with international pharmaceutical giants in overseas market expansion is yet another affirmation of Cellular Biomedicine Group (Shanghai) Ltd. The company will promote the process of achieving commercial-scale production according to international standards, significantly reducing the time cycle from therapy development to reaching patients' bedsides. In the future, the company will continue to increase R&D investment and enhance its innovation capabilities and production standards to meet the rapidly growing global demand for CAR-T cell therapies, igniting the light of hope for more patients to overcome diseases."
About Cellular Biomedicine Group
Cellular Biomedicine Group is a clinical-stage global biopharmaceutical company with innovation centers in Shanghai, China, and Maryland, USA. It focuses on developing innovative cell therapy products and is committed to combating malignant hematologic tumors, solid tumors, inflammation, and immune diseases through personalized treatments that harness the body's own immune system. The company has GMP-compliant production facilities at each of its innovation centers to advance product development and early clinical research, with a pipeline covering CAR-T and TIL therapies.
Forward-Looking Statements
The statements in this communication related to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results may differ materially from current expectations due to various factors, including any risks detailed from time to time in the company’s reports. Such statements are based on the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties outside the control of the company. In view of these uncertainties, you should not place undue reliance on these forward-looking statements, which are only valid as of the date of this document. Unless required by law, the company assumes no obligation and expressly disclaims any obligation to update, alter, or otherwise revise any forward-looking statements, whether made orally or in writing, due to new information, future events, or other reasons.
E.N.D
Previous article recommendations:
Yi尊生物 Completes Nearly 100 Million Yuan in A+ Round Financing
Bi Jingquan: Understanding Innovative Drugs from the Perspective of Innovation and Clinical Value
Global Well-Known Investment Bank: It's Time to Invest in Biotechnology
New Gene Therapy Vector Unveiled! Promising Effective and Safe Repeated Dosing
Sanofi Shuts Down NK Cell Therapy Company Acquired for Hundreds of Millions of Dollars
Cell Therapy Enters the Era of Solid Tumors
U.S. Biosecurity Bill May Include More Chinese CXO Companies
World's First Patient to Receive Genetically Edited Pig Kidney Transplant Discharged Successfully
Legend Biotech's CAR-T Drug CARVYKTI® Approved for Second-Line Indication in the U.S.
U.S. Congress Hawks on China Seek to Add BGI, Novozymes to Pentagon Warning List
US Intelligence Official: WuXi AppTec Transfers US Client Intellectual Property to China
NeuroD1 Gene Therapy by Shenxi Biotechnology Successfully Administers First Patient Globally